iTeos Therapeutics, Inc. - ITOS STOCK NEWS

iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical firm, will have its CEO Michel Detheux, PhD, participate in a panel at the William Blair Biotech Focus Conference 2021 on July 14, 2021, at 2:10 p.m. ET. The discussion will revolve around developing therapies for new immuno-oncology targets. A live webcast of the event will be available on the company’s website, with an archived replay accessible for 30 days post-event. iTeos focuses on innovative immuno-oncology therapeutics, with clinical programs such as EOS-448 and inupadenant showing promising early results.

iTeos Therapeutics (ITOS) and GlaxoSmithKline (GSK) have announced a collaboration to co-develop EOS-448, an anti-TIGIT monoclonal antibody, currently in phase I for advanced solid tumors. Under this agreement, iTeos will receive a $625 million upfront payment, with potential milestone payments totaling up to $1.45 billion. GSK will co-commercialize EOS-448 in the US, sharing profits, while receiving exclusive commercialization rights outside the US, along with tiered royalties. The partnership aims to enhance immuno-oncology therapies targeting the CD226 axis.

iTeos Therapeutics (NASDAQ: ITOS) announced positive results from its Phase 1/2a trial of inupadenant (EOS-850), an A_2AR antagonist, at ASCO 2021. Out of 43 patients, five showed durable responses or stable disease for over six months, including noteworthy results in melanoma and non-small cell lung cancer cases. Preliminary analyses suggest that A_2AR expression correlates with clinical outcomes. The monotherapy was well-tolerated, with serious adverse events not indicating new safety concerns. iTeos plans further trials combining inupadenant with pembrolizumab and chemotherapy.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 8:00 a.m. ET. A live webcast will be available on the company's website, with an archived replay for 30 days. iTeos focuses on developing innovative immuno-oncology therapeutics, including EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Both candidates are undergoing clinical trials showcasing preliminary clinical activity in adult patients with advanced solid tumors.

iTeos Therapeutics (NASDAQ: ITOS) reported its Q1 2021 financial results, highlighting a cash balance of $321.4 million to support ongoing clinical advancements. The company is progressing in its development of two lead programs, EOS-448 and inupadenant, with significant clinical data expected before the end of 2022. EOS-448 showed promising initial results in its Phase 1 trial, while inupadenant's updated data will be presented at the upcoming ASCO Annual Meeting. R&D expenses increased to $11.6 million, reflecting heightened clinical activity.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call and live webcast on May 13, 2021, at 4:30 p.m. ET to discuss its first quarter 2021 financial results and provide a corporate update. The company focuses on developing immuno-oncology therapeutics, with key programs including EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Both candidates are currently undergoing clinical trials to evaluate their effectiveness in treating advanced solid tumors.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) has appointed Dr. Tony Ho and Dr. Robert Iannone to its Board of Directors, enhancing the company's expertise in clinical drug development. CEO David Hallal emphasized their vast experience in driving oncology products through clinical phases, which will be crucial as iTeos progresses its EOS-448 and inupadenant programs. Both appointees have significant backgrounds in the pharmaceutical industry, which may accelerate iTeos' immuno-oncology pipeline aimed at improving cancer treatment outcomes.

iTeos Therapeutics (NASDAQ: ITOS) announced initial results from its Phase 1/2a trial for EOS-448, an anti-TIGIT antibody, showing it was well tolerated without dose-limiting toxicities. In a cohort of 22 patients, EOS-448 demonstrated a partial response in one pembrolizumab-resistant melanoma patient and stable disease in several others. The company plans to advance EOS-448 into combination trials with pembrolizumab and conduct further analysis on its effectiveness against various advanced cancers. A conference call is scheduled for April 12 to discuss the findings.

iTeos Therapeutics (ITOS) announced significant developments in their clinical programs, including initial Phase 1/2a trial data for EOS-448 to be presented at the AACR Annual Meeting on April 12. The company reported a strong cash position of $336.3 million, enabling ongoing clinical advancements and investment in research. Inupadenant (EOS-850) is also in a multi-arm trial, with updates expected later in 2021. The firm is making strides in immuno-oncology, aiming to nominate an additional product candidate by year-end.